Edimer Pharmaceuticals, Inc.
Records under this name other than patents Edimer Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Edimer Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,925,239 | Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein Formerly held In force · High confidence | In force | High confidence | |
| US 10,426,819 | Treatment of X-Linked Hypohidrotic Ectodermal Dysplasia with a Fusion EDA1 Protein Formerly held In force · High confidence | In force | High confidence | |
| US 9,175,085 | Treatment of X-linked Hypohidrotic Ectodermal Dysplasia with Ectodysplasin A Agonist Formerly held In force · High confidence | In force | High confidence | |
| US 9,695,245 | Anti-ectodysplasin antibodies Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,300,013 | Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,741,297 | Preparation of isolated agonist anti-EDAR monoclonal antibodies Formerly held Lapsed on the fee record Ended Jun 3, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | USPTO record |
| US 8,496,937 | Preparation of isolated agonist anti-EDAR monoclonal antibodies Formerly held Lapsed on the fee record Ended Jul 30, 2025 · USPTO record | Lapsed on the fee record | Ended Jul 30, 2025 | USPTO record |